BeOne Medicines showcases breakthrough data at EHA

Sino-American oncology company BeOne Medicines (Nasdaq: ONC), previously called BeiGene, is presenting new clinical data from cornerstone hematology assets at the European Hematology Association (EHA) Congress.

Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of its hematology franchise, BTK inhibitor Brukinsa (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies.

“The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of Brukinsa, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase III trial,” said Lai Wang, global head of R&D at BeOne, adding: “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and first-in-class BTK degrader, BGB-16673, we are advancing innovative therapies aimed at addressing resistance mechanisms and improving outcomes for patients with B-cell malignancies.”